Polypeptides de fusion IGF-1 et utilisations thérapeutiques

• 收藏
• 分享

专利权人:

REGENERON PHARMACEUTICALS; INC.

发明人:

申请号：

EP10007017.6

公开号：

EP2241575B1

申请日:

2006.01.06

申请国别(地区):

EP

年份:

2015

代理人:

摘要：

A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibiting improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, a targeting ligand, or another active or therapeutic compound. IGF1 variants were shown to have improved ability to induce skeletal muscle hypertrophy relative to native IGF1.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/